OSTX
OS Therapies Incorporated
0.8722
-0.04 (-4.48%)
52w low 0.5800
2.25 high
17.5% of range
Open
0.8964
High
0.9400
Low
0.8600
Prev Close
0.9131
Volume
327.35K
Avg Vol 3M
670.38K
Market Cap
40.82M
Currency
USD
6 Month Trend
—
C--
Chg--
Gap--
Vol--
×avg--
σ--
SMA20--
SMA50--
SMA200--
RSI--
SPY--
DD--
Bench--
Sig--
Hist--
pinned · Esc to release
hover · click to pin · ← → step · drag to zoom · shift-drag to measure
—Context
- Move across the chart.
Company
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| Employees | 4 |
| Web | site ↗ |
Performance
1D
-2.00%
5D
-24.16%
1M
-44.09%
3M
-45.83%
6M
-51.27%
YTD
-37.70%
1Y
-53.85%
2Y
-67.46%
3Y
--
5Y
--
MAX
-78.93%
Valuation
| P/E Trailing | -- |
| P/E Forward | 2.54x |
| Price / Book | -3.38x |
| Price / Sales | -- |
| EV / EBITDA | -1.17x |
| EPS Trailing | -1.08 |
| Dividend Yield | 0.00% |
| Beta | -0.47 |
Profitability
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -- |
| Return on Assets | -232.65% |
| Revenue Growth | -- |
| Debt / Equity | -- |
| Current Ratio | 0.18x |
Business
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.